Getting the Best Dose: The Clinical Pharmacology Studies that Help Achieve this Goal
Brian Booth, PhD, director of the Division of Cancer Pharmacology 1 in the Office of Clinical Pharmacology (OCP), Office of Translational Science (OTS), discusses how various clinical pharmacology studies provide better understanding of dose optimization for different types of patients. Learn more at: https://www.fda.gov/drugs/news-events... -------------------- FDA CDER’s Small Business and Industry Assistance (SBIA) educates and provides assistance in understanding the regulatory aspects of human drug products & clinical research. Upcoming Training - https://www.fda.gov/cdersbia SBIA Listserv - https://public.govdelivery.com/accoun... SBIA 2021 Playlist - • 2021 CDER Small Business and Industry Assi... SBIA LinkedIn: / cder-small-business-and-industry-assistance SBIA Training Resources - https://www.fda.gov/cdersbialearn Twitter - / fda_drug_info Email - [email protected] Phone - (301) 796-6707 I (866) 405-5367
Clinical Development of Radiopharmaceuticals a Theranostic Pairs and Dosimetry Considerations
AGDD 2025 | D2S03 - Common Deficiencies and Resolutions: Complex Drug Substance/Excipients/Products
FDA Grand Rounds - Clinical Omics Biomarker Discovery and Validation in Precision Medicine
OTC Monograph Reform: OTC Sunscreen Drugs
AGDD 2025 | D1S02 - Novel Bioequivalence Study Design Recommendations
FDA Direct: The Power of Real-Time Clinical Trials
Designing First-In-Human Trials for Small Molecules and Biologics
FDA Direct: An Eye on CDRH: Regulating for a New Era of Medical Devices
Drug Master File (DMF) Submissions on New FDA Form 3938
Understanding the Nutrition Facts Label, the Updated “Healthy” Claim, and Other Nutrition Claims
FDA Direct: FDA is Not Your Doctor - Discussing FDA's Role and Mandate
Getting to First-in-Human for Small Molecules and Biologics
Advancing Real-Time Clinical Trials
Commissioner’s National Priority Voucher (CNPV) Pilot Program Public Hearing
AGDD 2025 | D2S04 - Nitrosamines: Known Issues and Practical Advice
OTP Town Hall: Best Practices for Preparing BLA Submissions for Cell and Gene Therapy Products
AGDD 2025 | D1S01 - Product-Specific Guidance for Complex Products: From Research to Standards
FDA Direct: These 9 Drugs Were Awarded National Priority Vouchers
Conversations on Cancer: Patient first = Project Facilitate
